

# THE LATEST CLINICAL CONSIDERATIONS FOR NSCLC: A GLOBAL APPROACH

## 21 GIUGNO 2021 WEBINAR FAD SINCRONA

Chair  
**FEDERICO CAPPUZZO**  
IFO-ROME



14:30 **Introduction** Federico Cappuzzo (Rome)

### CURRENT RATIONALE FOR THE SELECTION OF IMMUNOTHERAPY

14:40 **Biomarker tests in metastatic NSCLC** Lucio Crinò (Meldola - Forlì)

14:50 **Role of PD-1 and PD-L1** Silvia Novello (Turin)

15:00 **How homologous recombination repair deficiencies (HRD) and DNA mismatch repair deficiencies are impacting decisions to use immunotherapy**  
Federico Cappuzzo (Rome)

15:10 **Discussion on session topics**

### EARLY STAGE NSCLC

15:15 **PACIFIC 5-years survival data: Is the milestone reached for talking about curative intent?**

15:20 **Do we have any news regarding early stage of NSCLC treatment? Is there any role for precision medicine in this disease setting?**  
Federico Cappuzzo (Rome) - Lucio Crinò (Meldola - Forlì)  
Silvia Novello (Turin)



### HOW TO DETERMINE WHEN TO USE MONOTHERAPY VERSUS COMBINATION THERAPY?

15:30 **When immunotherapy as monotherapy is appropriate** Silvia Novello (Turin)

15:40 **When immunotherapy combinations with chemotherapy are appropriate**  
Federico Cappuzzo (Rome)

15:50 **When IO/IO combinations are appropriate**  
Lucio Crinò (Meldola - Forlì)



16:00 **Discussion on session topics**

### NEW DATA ON IMMUNOTHERAPY

16:10 Federico Cappuzzo (Rome)

- **Cemiplimab mono vs platinum-doublet chemo**
- **New combinations - anti-TIGIT agent**

16:30 Lucio Crinò (Meldola - Forlì)

- **Mutations and irAEs predicting IO response**
- **Pembro + ipilimumab vs pembro monotherapy**
- **3-year survival data**

16:50 Silvia Novello (Turin)

- **What to do with patients progressing after IO**

### TARGET THERAPIES. EMERGING DATA ON NEW AGENTS THAT WILL IMPACT OUR STANDARD OF PRACTICE

17:10 **EGFR TKIs including exon 20 inhibitors** Silvia Novello (Turin)

17:20 **HER2 inhibitors** Federico Cappuzzo (Rome)

17:30 **ALK, ROS1 and KRAS inhibitors**

17:40 **OPTIONS IN Rearranged NSCLC**

17:50 **Discussion: new approach for oncogene addicted NSCLC and implications for immunotherapy particularly in KRAS mut+ STK11+ All panelists**

18:00 **Take home message** Federico Cappuzzo (Rome)

#### ISCRIZIONI

Accedere a <https://fad.mitcongressi.it>  
Cliccare ACCEDI (in caso di 1° accesso procedere con registrazione).  
Ultimata la registrazione, procedere con ACCESSO inserendo email e password  
Selezionare dal CATALOGO il corso desiderato

**3 CREDITI ECM** per:  
MEDICO CHIRURGO

(Allergologia ed Immunologia Clinica, Anatomia Patologica, Chirurgia Generale, Chirurgia Toracica, Genetica Medica, Malattie dell'Apparato Respiratorio, Medicina Nucleare, Oncologia, Patologia Clinica, Radiodiagnostica, Radioterapia, Cure Palliative)  
FARMACISTA  
(Farmacia Ospedaliera, Farmacia Territoriale)  
BIOLOGO  
TECNICO SANITARIO RADIOLOGIA MEDICA  
TECNICO SANITARIO LAB. BIOMEDICO  
INFERMIERE

SEGRETERIA ORGANIZZATIVA E PROVIDER  
Centro Direzionale Bolomina  
Via Guelfa, 5 - 40138 Bologna  
[www.mitcongressi.it](http://www.mitcongressi.it)



CON IL CONTRIBUTO INCONDIZIONATO DI:

